Plasma/Serum Cell-Free Circulating DNA Purification Kits
For rapid and simple purification of cell-free circulating DNA from plasma/serum samples
For research use only and NOT intended for in vitro diagnostics.
CE-IVDR marked diagnostic versions available here
Plasma/Serum Cell-Free Circulating DNA Purification Kits
For rapid and simple purification of cell-free circulating DNA from plasma/serum samples
Register today to receive an exclusive 15% off* on your first order.
Features and Benefits
- Isolate all sizes of circulating DNA from plasma and serum samples
- Isolate viral and bacterial DNA
- Versatile plasma and serum input volumes
- Concentrate circulating DNA into a flexible elution volume
- Isolate inhibitor-free cell-free circulating DNA
- Compatible with Streck Cell-Free DNA BCT® Tubes
- Purification is based on spin column chromatography that uses Norgen’s proprietary resin separation matrix
These kits provide a fast, reliable and convenient spin column method for the isolation of high quality, high purity and inhibitor-free cell-free circulating DNA (cfc-DNA) from plasma/serum sample volumes. The purified plasma/serum cfc-DNA is fully compatible with all downstream applications including PCR, qPCR, methylation-sensitive PCR and Southern Blot analysis, microarrays and NGS.
Background
Plasma/Serum cell-free circulating DNA (cfc-DNA) has the potential to provide biomarkers for certain cancers and disease states as well as fetal DNA in maternal blood. Currently, significant advancements are being made in utilizing cfc-DNA as biomarkers for the early diagnosis, prognosis and monitoring of therapy for several cancer types and autoimmune diseases. Cell-free mitochondrial DNA (cfmtDNA) is also under investigation for its clinical significance. This cfc-DNA is usually present as short fragments of less than 1000 bp. In addition, cell-free fetal DNA has been widely used as a non-invasive method for prenatal diagnosis including early identification of fetal sex, genetic studies for families at high risk for inherited genetic disorders, screening for Rhesus factor, screening for aneuploidy and identification of preeclampsia.
Plasma/Serum Cell-Free Circulating DNA Purification Micro Kit
Ideal for handling initial plasma/serum volumes ranging from 10 μL up to 200 μL. The kit is designed to isolate all sizes of cfc-DNA from either fresh or frozen plasma/serum samples and the purified DNA is eluted into a flexible elution volume ranging from 25 µL to 50 µL.
Plasma/Serum Cell-Free Circulating DNA Purification Mini Kit
Ideal for handling initial plasma/serum volumes ranging from 200 μL up to 500 μL. The kit is designed to isolate all sizes of cfc-DNA from either fresh or frozen plasma/serum samples and the purified DNA is eluted into a flexible elution volume ranging from 25 µL to 50 µL.
Plasma/Serum Cell-Free Circulating DNA Purification Midi Kit
Ideal for handling initial plasma/serum volumes ranging from 1 mL - 4 mL. The first column will handle the large volume input of bodily fluids that is followed by a concentration on a mini column for a final elution of 25 µL to 50 µL
Plasma/Serum Cell-Free Circulating DNA Purification Maxi Kit
Ideal for handling initial plasma/serum volumes ranging from 5 mL- 10 mL. The first column will handle the large volume input of bodily fluids that is followed by a concentration on a mini column for a final elution of 25 µL to 50 µL
Details
Supporting Data
Kit Specifications | |
Minimum Plasma/Serum Input | 10 μL |
Maximum Plasma/Serum Input | 200 μL |
Size of DNA Purified | ≥ 50 bp |
Elution Volume | 25-50 μL |
Time to Complete 10 Purifications | 15-20 minutes |
Average Yields* | Variable depending on specimen |
*Please check page 7 in the product manual for the Plasma/Serum Average Yields and the Common DNA Quantification Methods.
Storage Conditions and Product Stability
All solutions should be kept tightly sealed and stored at room temperature. This kit is stable for 2 years after the date of shipment. The kit contains a ready-to-use Proteinase K, which is dissolved in a specially prepared storage buffer. The buffered Proteinase K is stable for up to 2 years after the date of shipment when stored at room temperature.
Component | Cat. 55500 (50 preps) | Cat. 55100 (50 preps) | Cat. 55600 (20 preps) | Cat. 55800 (10 preps) |
---|---|---|---|---|
Binding Buffer B | 40 mL | 2 x 40 mL | 2 x 85 mL 1 x 12 mL |
2 x 85 mL 1 x 40 mL |
Proteinase K | 0.6 mL | 2 x 1 mL | 6.5 mL | 8 mL |
Solution WN | 18 mL | 18 mL | 18 mL | 18 mL |
Wash Solution A | 18 mL | 38 mL | 18 mL | 18 mL |
Elution Buffer B | 8 mL | 8 mL | 30 mL | 30 mL |
Micro Spin Columns | 50 | 50 | 20 | 10 |
Mini Spin Columns | - | 50 | - | - |
Midi Spin Columns | - | - | 20 | - |
Maxi Spin Columns | - | - | - | 10 |
Collection Tubes | 50 | 100 | 20 | 10 |
Elution Tubes (1.7 mL) | 50 | 100 | 20 | 10 |
Product Insert | 1 | 1 | 1 | 1 |
Documentation
(55100) Plasma/Serum Cell-Free Circulating DNA Purification Kits - Protocol (50 Preps)
(55600) Plasma/Serum Cell-Free Circulating DNA Purification Kits - Protocol (20 Preps)
(55800) Plasma/Serum Cell-Free Circulating DNA Purification Kits - Protocol (10 Preps)
55100 - Plasma/Serum Cell-Free Circulating DNA Purification Mini Kit - SDS
55600 - Plasma/Serum Cell-Free Circulating DNA Purification Midi Kit - SDS
55800 - Plasma/Serum Cell-Free Circulating DNA Purification Maxi Kit - SDS
FAQs
Micro, Mini, Midi, Maxi
Citations
Title | Exploring mitochondrial DNA copy number in circulating cell-free DNA and extracellular vesicles across cardiovascular health status: A prospective case-control pilot study |
Citation | The FASEB journal 2024. |
Authors | Chiara Rucci1,2 | Gaia de Simone1,2 | Saniya Salathia3 | Cristina Casadidio3 | Roberta Censi3 | Laura Bordoni |
Title | Monitoring of plasma circulating donor DNA reflects cardiac graft injury: Report of two cases |
Citation | BIOMEDICAL REPORTS 2024. |
Authors | DANA DLOUHA1 , PAVLINA HUCKOVA1 , EVA ROHLOVA1-3, JEVGENIJA VYMETALOVA4 , SARKA NOVAKOVA1 and JAROSLAV A. HUBACEK |
Title | Plasma cfDNA abundance as a prognostic biomarker for higher risk of death in geriatric cardiovascular patients |
Citation | Mechanisms of Ageing and Development 2024. |
Authors | Maurizio Cardelli a, Francesca Marchegiani b, Pierpaolo Stripoli b, Francesco Piacenza a, Rina Recchioni b, Mirko Di Rosa c, Robertina Giacconi a, Marco Malavolta a, Roberta Galeazzi b, Beatrice Arosio d e, Fiammetta Cafarelli f, Francesco Spannella g h, Antonio Cherubini i, Fabrizia Lattanzio j, Fabiola Olivieri |
Title | Urine-Based Biomarker Test Uromonitor® in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer— A Systematic Review and Meta-Analysis of Diagnostic Test Performance |
Citation | Cancers 2024. |
Authors | Anton P. Kravchuk 1,†, Ingmar Wolff 2,*,†, Christian Gilfrich 1, Ralph M. Wirtz 3, Paula Soares 4,5, Kay-Patrick Braun 6, Sabine D. Brookman-May 7,8, Lisa Kollitsch 9, Katharina Hauner 10, Martin Burchardt 2, Johannes Bründl 11, Maximilian Burger 11,‡ and Matthias May 1,‡ |
Title | Abstract 6012: Comparison of pre-analytical methods for DNA methylation analysis of cfDNA |
Citation | Cancer Res 2023. |
Authors | Miljana Tanic; Oluwadunni Emiloju; Pawan Dhami; Stephan Beck |
Title | Are elevated mitochondrial DNA fragments in prostatic inflammation a potential biomarker for prostate cancer? |
Citation | Original Papers - Prostate 2023. |
Authors | Ugur Aferin, Nurten Bahtiyar, Ilhan Onran & Hamdi Ozkara |
Title | Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids |
Citation | Human genomics 2023. |
Authors | Jaeryuk Kim, Seung-Pyo Hong, Seyoon Lee, Woochan Lee, Dakyung Lee, Rokhyun Kim, Young Jun Park, Sungji Moon, Kyunghyuk Park, Bukyoung Cha & Jong-Il Kim |
Title | Significance of Circulating Cell-Free DNA Biomarkers in HBeAg-Negative Chronic Hepatitis B Virus Infection and Their Changes after Treatment Initiation |
Citation | Pathogens 2023. |
Authors | Nikolaos D. Karakousis ,Lampros Chrysavgis,Alkistis Papatheodoridi, Aigli-Ioanna Legaki ,Panagiotis Lembessis ,Evangelos Cholongitas ,Antonios Chatzigeorgiou, and George Papatheodoridis |
Title | Application and optimization of minimally invasive cell-free DNA techniques in oncogenomics |
Citation | Tumor Biology 2018. |
Authors | Kumar, M., Choudhury, Y., Ghosh, S. K., & Mondal, R. (2018). |
Title | Immunohistochemical evaluation of stressresponsive protein sestrin2 and its correlation with p53 mutational status in eyelid sebaceous gland carcinoma |
Citation | British Journal of Ophthalmology 2018. |
Authors | Jayaraj, P., Sen, S., Rangarajan, S., Ray, N., Vasu, K., Singh, V. K., ... & Verma, A. (2018). |